Dulaglutide vs Melanotan II
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Dulaglutide
Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist for type 2 diabetes. Its larger molecular size from fusion with an Fc fragment extends half-life and may reduce some GI side effects.
Full details →Melanotan II
Melanotan II is a synthetic peptide analog of α-MSH with broader receptor activity than Melanotan I. It produces tanning effects and has notable effects on sexual function and appetite suppression.
Full details →Side-by-Side Comparison
| Aspect | Dulaglutide | Melanotan II |
|---|---|---|
| Dose Range | 750 mcg–4.5 mg | 250 mcg–1 mg |
| Frequency | Less than daily | 1x daily |
| Cycle Length | 12–52 weeks | 1–2 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | GLP-1 analog fused to a modified human IgG4 Fc fragment, providing extended duration of action. Activates GLP-1 receptors for glucose-dependent insulin secretion and appetite suppression. | Non-selective melanocortin receptor agonist affecting MC1R (tanning), MC3R and MC4R (sexual function and appetite). This broader activity explains its multiple effects beyond tanning. |
| Typical Dosage | Start at 0.75mg once weekly, may increase to 1.5mg, 3mg, or maximum 4.5mg weekly based on glycemic response. | Typical protocols: 0.25-0.5mg daily during loading phase for 1-2 weeks, then 0.5-1mg before UV exposure for maintenance. Start low to assess tolerance. |
| Administration | Subcutaneous injection once weekly, any time of day, with or without food. Comes in pre-filled single-dose pens. | Subcutaneous injection. Usually combined with UV exposure for tanning effects. Nasal spray formulations exist but have lower bioavailability. |
| Side Effects | Nausea, diarrhea, vomiting, abdominal pain, decreased appetite. Generally well-tolerated with gradual dose titration. | Nausea (common initially), facial flushing, spontaneous erections, increased libido, appetite suppression, and mole darkening. |
| Best For |
What They Have in Common
Dulaglutide, Melanotan II are both commonly used for:
Key Differences
Unique to Melanotan II:
Which Has Stronger Evidence?
- Fat Loss: Dulaglutide has stronger research support.
| Goal | Dulaglutide | Melanotan II |
|---|---|---|
| Fat Loss | high | low |
Key Studies
Dulaglutide
- Comparative Gastrointestinal Safety of Dulaglutide, Semaglutide, and Tirzepatide in Adults With Type 2 Diabetes.
Annals of internal medicine, 2026
- Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes.
Nature, 2026
- Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial.
JAMA cardiology, 2026
Melanotan II
- Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma?
International journal of oral and maxillofacial surgery, 2025
- Melanotan II User Experience: A Qualitative Study of Online Discussion Forums.
Dermatology (Basel, Switzerland), 2021
- Melanotan II, a melanocortin agonist, partially rescues the impaired thermogenic capacity of pituitary adenylate cyclase-activating polypeptide deficient mice.
Experimental physiology, 2021
Ready to Learn More?
Looking for trusted sources?